View Older Stories View More Recent Stories
-
Form SC 13G Tenaya Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases
-
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
-
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
-
Ultrasound Disruptor Exo Secures $220M in Series C Funding Round
-
Form SC 13G TScan Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Thriveworks Partners with Wellington Management
-
Form SC 13G ARYA Sciences Acquisitio Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
-
Novo Holdings co-leads Hemab's US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
-
AavantiBio and Aldevron Announce Strategic Partnership to Develop Next Generation Gene Therapies for Rare Genetic Diseases
-
Form SC 13G POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Form SC 13D Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
-
Form SC 13D Aerovate Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Aerpio Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adcendo Appoints Michael Pehl as Chief Executive Officer
-
Form SC 13G Entera Bio Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Therapeutics Acquisition Filed by: RA CAPITAL MANAGEMENT, L.P.
-
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
-
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
-
Form SC 13G Cyteir Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Pardes Biosciences and FS Development Corp. II (FSII) Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company
-
Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections
-
POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs
-
POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs
-
Form 3 Therapeutics Acquisition For: Jun 23 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases
-
Form SC 13G Novan, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
LENZ Therapeutics Debuts With $47 Million Series A Financing
-
Form SC 13D Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
DTx Pharma to Participate in the 2021 BMO BioPharma Day: Spotlight on Rare Disease and Ophthalmology
-
Form SC 13G CATABASIS PHARMACEUTICAL Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform
-
Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome
-
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
-
ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes
-
Form SC 13D/A Connect Biopharma Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Day One Biopharmaceutica Filed by: RA CAPITAL MANAGEMENT, L.P.
-
PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments
-
DTx Pharma Appoints Jill Howe as Chief Financial Officer
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
POINT Biopharma Doses First Patients in Phase 3 Study of PNT2002 for mCRPC (RACA)
-
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
-
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
